Clinical Study of the Safety and Efficacy of the R/R B-NHL Regimen With BTK Inhibitor+Anti-CD19 CAR-T Cells

NCT05744037 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

B-cell Non Hodgkin Lymphoma

Interventions

BIOLOGICAL: regimen with BTK inhibitor +Anti-CD19 CAR T cells

Sponsor

The Affiliated Hospital of Xuzhou Medical University